Precipio Presents Findings from 895-Patient BCR::ABL1 Assay Study at ASH
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Globenewswire
- Study Findings Presentation: Precipio will present findings from a joint study with Memorial Sloan Kettering at the ASH meeting, involving 895 patient samples, demonstrating superior performance of the BCR::ABL1 assay, which enhances patient care and optimizes laboratory workflows.
- Significant Clinical Impact: The study shows that the BCR::ABL1 assay exhibits high concordance with two leading platforms, not only improving diagnostic accuracy but also potentially reducing cancer misdiagnosis rates, thereby enhancing treatment outcomes for patients.
- Industry Recognition: The poster presentation and results discussion scheduled for December 8 will further elevate Precipio's standing in the cancer diagnostics field, attracting increased attention and investment.
- Innovation-Driven Growth: Precipio's commitment to developing more efficient diagnostic products to address cancer misdiagnosis is reinforced by these study results, which will drive the company's expansion in the global laboratory market and strengthen its competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRPO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRPO
About PRPO
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Launches New Immunology Drugs, Stock Up 31.6% Over Last Year
- New Drug Launch: AbbVie has successfully launched two new immunology drugs, Skyrizi and Rinvoq, which are expected to support revenue growth in the coming years following Humira's loss of exclusivity.
- Market Performance: AbbVie’s stock has risen 31.6% over the past year, significantly outperforming the 19.5% growth of the large-cap pharmaceuticals industry, indicating strong competitive positioning.
- Acquisition Strategy: The company has engaged in a series of acquisitions over the past few years to bolster its early-stage pipeline, aiming for long-term growth despite challenges from Humira's patent expiration.
- Diversified Product Line: AbbVie's oncology and neuroscience drugs are also contributing to revenue growth, further solidifying its position in the pharmaceutical industry.
Continue Reading
Precipio Presents Findings from 895-Patient BCR::ABL1 Assay Study at ASH
- Study Findings Presentation: Precipio will present findings from a joint study with Memorial Sloan Kettering at the ASH meeting, involving 895 patient samples, demonstrating superior performance of the BCR::ABL1 assay, which enhances patient care and optimizes laboratory workflows.
- Significant Clinical Impact: The study shows that the BCR::ABL1 assay exhibits high concordance with two leading platforms, not only improving diagnostic accuracy but also potentially reducing cancer misdiagnosis rates, thereby enhancing treatment outcomes for patients.
- Industry Recognition: The poster presentation and results discussion scheduled for December 8 will further elevate Precipio's standing in the cancer diagnostics field, attracting increased attention and investment.
- Innovation-Driven Growth: Precipio's commitment to developing more efficient diagnostic products to address cancer misdiagnosis is reinforced by these study results, which will drive the company's expansion in the global laboratory market and strengthen its competitive edge.
Continue Reading